Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Josep Rodés-Cabau Added: 2 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more
Author(s): Atul Verma Added: 1 week ago
AHA 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter ablation of AF, left… View more
Author(s): Jeffrey Weitz , Carolyn Lam , Davide Capodanno , et al Added: 2 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore… View more
Author(s): Yan Yan , Gilles Montalescot Added: 2 years ago
ESC 23 — Dr Yan Yan (Beijing Anzhen Hospital, CN) and Prof Gilles Montalescot (Pitie Salpetriere APHP University Hospital,FR) discusses the findings from a comparison of anticoagulation prolongation vs no anticoagulation in STEMI patients post-primary PCI (RIGHT) (NCT03664180). The RIGHT study (Beijing Anzhen Hospital) aimed to evaluate the clinical efficacy and safety of anticoagulation… View more
Author(s): Paulus Kirchhof Added: 2 years ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,… View more